Semorinemab: anti-tau drug fails Phase II clinical trial for early Alzheimer’s disease

Written by Sharon Salt, Senior Editor

Genentech (CA, USA) has informed AC Immune (Lausanne, Switzerland) of top-line results from a Phase II trial (TAURIEL) of the anti-tau antibody, semorinemab, for early Alzheimer’s disease. The trial demonstrated that semorinemab did not meet its primary efficacy endpoint of reducing decline on Clinical Dementia Rating-Sum of Boxes (CDR-SB) compared with placebo. The TAURIEL trial was a 73-week, double-blind, placebo-controlled study to determine if semorinemab could slow the rate of clinical decline in early Alzheimer’s disease. The study followed 457 participants across 97 study centers. Two secondary endpoints, the Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13) and Alzheimer’s Disease Cooperative...

To view this content, please register now for access

It's completely free